HLA-DQ2 peptide vaccine - ImmusanT

Drug Profile

HLA-DQ2 peptide vaccine - ImmusanT

Alternative Names: Coeliac disease peptide vaccine - ImmusanT; HLA-DQ2.5 peptide vaccine - ImmusanT; Nexvax2

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nexpep
  • Developer ImmusanT
  • Class Immunotherapies; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Coeliac disease

Most Recent Events

  • 21 May 2018 ImmusanT plans a phase II trial for Coeliac disease in the third quarter of 2018
  • 01 May 2018 Phase-I clinical trials in Coeliac disease in Australia (SC) (NCT03543540)
  • 28 Oct 2017 Safety, pharmacokinetics and pharmacodynamics data from a phase I trial in Coeliac Disease presented at the 25th United European Gastroenterology Week (UEGW-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top